Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors
March 01, 2022 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology...
Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology...
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
December 22, 2021 07:00 ET
|
Mereo BioPharma Group plc
Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of...
Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting
December 13, 2021 07:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology...
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors
November 30, 2021 07:00 ET
|
Mereo BioPharma Group plc
One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set Etigilimab was well tolerated with a favorable safety profile ...
Mereo BioPharma to Present at Two Upcoming Investor Conferences
November 09, 2021 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology...
Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
November 04, 2021 09:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology...
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency
October 26, 2021 08:00 ET
|
Mereo BioPharma Group plc
LONDON and REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology...
Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment
October 13, 2021 08:00 ET
|
Mereo BioPharma Group plc
Living With Osteogenesis IMPerfecta: UnderstAnding Experiences Based On Community InsighT and Evidence Survey, the IMPACT SurveyMore than 2200 individual responses collected over a 3-month period from...
Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
October 01, 2021 16:31 ET
|
Mereo BioPharma Group plc
Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consistent across subtypes of OI ...